Evidence map›Paper›PMID 34695724›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2021

Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.

Christopher D Heaney, Nora Pisanic, Pranay R Randad, Kate Kruczynski, Tyrone Howard, Xianming Zhu, Kirsten Littlefield, Eshan U Patel, Ruchee Shrestha, Oliver Laeyendecker and 11 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Christopher D HeaneyDepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Room W7033B Baltimore, MD, 21205 USA; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. Electronic address: cheaney1@jhu.edu.
Nora PisanicDepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Room W7033B Baltimore, MD, 21205 USA.
Pranay R RandadDepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Room W7033B Baltimore, MD, 21205 USA.
Kate KruczynskiDepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Room W7033B Baltimore, MD, 21205 USA.
Tyrone HowardDepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Room W7033B Baltimore, MD, 21205 USA.
Xianming ZhuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kirsten LittlefieldDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Eshan U PatelDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ruchee ShresthaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Oliver LaeyendeckerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore MD, USA.
Shmuel ShohamDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David SullivanDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kelly GeboDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel HanleyDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew D ReddDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore MD, USA.
Thomas C QuinnDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore MD, USA.
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Jonathan M ZenilmanDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew PekoszDepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, 615 North Wolfe Street, Room W7033B Baltimore, MD, 21205 USA; Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aaron A R TobianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USNational Institutes of Health · US

Funding

ECHODAC (Environmental Influences on Child Health Outcomes Data Analysis Center)U24OD023382 · OD · JOHNS HOPKINS UNIVERSITY · PI Diane J Catellier, LISA P JACOBSON · 2016 to 2026
$148.4M
Johns Hopkins-Tufts Trial Innovation Center HEAL Pain ERN SupplementU24TR001609 · NCATS · JOHNS HOPKINS UNIVERSITY · PI HANLEY, DANIEL F · 2016 to 2022
$36.3M
Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Conjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1M
Unlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3M
Antimicrobial resistant E. coli before and after California Senate bill 27 (ARES): a natural experimentR01AI130066 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI TARTOF, SARA · 2017 to 2021
$3.8M
Arsenic and immune response to influenza vaccination in pregnant women and newbornsR01ES026973 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI HEANEY, CHRISTOPHER D, LABRIQUE, ALAIN BERNARD · 2017 to 2021
$3.6M
Penile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1M
The Malaria Transfusion Risk (MATRix) StudyK23HL151826 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLOCH, EVAN MARTIN · 2020 to 2024
$882k
LONGITUDINAL STUDY OF DEPRESSION IN LUNG CANCERR01NR005228 · NINR · UNIVERSITY OF SOUTH FLORIDA · PI WEITZNER, MICHAEL A · 1999 to 2002
$550k
Multiplex oral fluid antibody assay for arbovirus diagnosis, surveillance and preventionR21AI139784 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COLLINS, MATTHEW, HEANEY, CHRISTOPHER D · 2018 to 2019
$459k
NCATS NIH HHS U24 TR001609NHLBI NIH HHS K23 HL151826NHLBI NIH HHS R01 HL059842NIAID NIH HHS R01 AI120938NIAID NIH HHS R01 AI128779NIAID NIH HHS R01 AI130066NIAID NIH HHS R01 AI152078NIAID NIH HHS R21 AI139784NIAID NIH HHS T32 AI102623NIEHS NIH HHS R01 ES026973NIH HHS U24 OD023382NINR NIH HHS R01 NR005228
6 · The paper itself

Abstract

Oral fluid (hereafter saliva) offers a non-invasive sampling method for detection of SARS-CoV-2 antibodies. However, data comparing performance of salivary tests against commercially-available serologic and neutralizing antibody (nAb) assays are lacking. This study compared the performance of a laboratory-developed multiplex salivary SARS-CoV-2 IgG assay targeting antibodies to nucleocapsid (N), receptor binding domain (RBD) and spike (S) antigens to three commercially-available SARS-CoV-2 serologic enzyme immunoassays (EIAs) (Ortho Vitros, Euroimmun, and BioRad) and nAb. Paired saliva and plasma samples were collected from 101 eligible COVID-19 convalescent plasma (CCP) donors >14 days since PCR+ confirmed diagnosis. Concordance was evaluated using positive (PPA) and negative (NPA) percent agreement, and Cohen's kappa coefficient. The range between salivary and plasma EIAs for SARS-CoV-2-specific N was PPA: 54.4-92.1% and NPA: 69.2-91.7%, for RBD was PPA: 89.9-100% and NPA: 50.0-84.6%, and for S was PPA: 50.6-96.6% and NPA: 50.0-100%. Compared to a plasma nAb assay, the multiplex salivary assay PPA ranged from 62.3% (N) and 98.6% (RBD) and NPA ranged from 18.8% (RBD) to 96.9% (S). Combinations of N, RBD, and S and a summary algorithmic index of all three (N/RBD/S) in saliva produced ranges of PPA: 87.6-98.9% and NPA: 50-91.7% with the three EIAs and ranges of PPA: 88.4-98.6% and NPA: 21.9-34.4% with the nAb assay. A multiplex salivary SARS-CoV-2 IgG assay demonstrated variable, but comparable performance to three commercially-available plasma EIAs and a nAb assay, and may be a viable alternative to assist in monitoring population-based seroprevalence and vaccine antibody response.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 Serological TestingCOVID-19 SerotherapyHumansImmunization, PassiveImmunoglobulin GSARS-CoV-2Sensitivity and SpecificitySeroepidemiologic StudiesSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GSpike Glycoprotein, CoronavirusCOVID-19Multiplex immunoassayNeutralizing antibodySalivaSARS-CoV-2Serologic assays

Identifiers

PMID34695724
PMCPMC8502080
OpenAlexW3205635394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.